David Mott
New Enterprise Associates General Partner
investment range
$200k - $40.0m
sweet spot
$10.0m
David Mott's Past Investments (14)
| Company | Deal Type | Amount | Date | |
|---|---|---|---|---|
| Sagimet Biosciences | Series E | $7M | Aug 2019 | |
| Nightstar Therapeutics | Series C | $45M | Jun 2017 | |
| Ardelyx | Post-IPO Equity | $110M | Jul 2016 | |
| Nightstar Therapeutics | Series B | $35M (Lead) | Nov 2015 | |
| Clementia Pharmaceuticals | Venture Round | $60M (Lead) | Jun 2015 | |
| Ardelyx | Post-IPO Equity | $77.8M (Lead) | Jun 2015 | |
| Adaptimmune | Series A | $104M (Lead) | Sep 2014 | |
| Cydan | Venture Round | $10M | Oct 2013 | |
| Edimer Pharmaceuticals | Series B | $18M (Lead) | Jul 2013 | |
| Cydan | Venture Round | $16M (Lead) | Apr 2013 |
David Mott's Media
No media found for David Mott.